



BLUE JET HEALTHCARE LIMITED

REGISTERED & CORPORATE : 701 & 702, BHUMIRAJ COSTARICA,
PLOT 1 & 2, SECTOR - 18, SANPADA, NAVI MUMBAI - 400705

T : 022- 41840550 / 40037603

F : +91 22 27814204

E : sales@bluejethealthcare.com

CIN NO. : L99999MH1968PLC014154

February 13, 2026

To,

The Manager Listing Department BSE Limited Phiroze Jeejebhoy Towers Dalal Street Mumbai - 400 001 Scrip Code (BSE): 544009	The Manager Listing Department National Stock Exchange of India Limited Exchange Plaza, Plot No. C/1, G Block, Bandra-Kurla Complex, Bandra (East) Mumbai - 400051 Symbol: BLUEJET
---	---

Sub.: Outcome of Board Meeting held today i.e, Friday, February 13, 2026.

Dear Sir / Ma'am,

In terms of Regulation 30 and Regulation 33 read with Schedule III and other applicable provisions of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform you that, the Board of Directors of the Company at their meeting held today viz. Friday, February 13, 2026, *inter-alia*, has approved the following: -

- Unaudited Standalone Financial Results of the Company for the quarter and nine months ended December 31, 2025. A signed copy of the Unaudited Standalone Financial Results along with the Limited Review Report thereon is enclosed herewith.

The meeting commenced at 12:42 P.M. and concluded at 01:10 P.M.

Kindly take the same on your record.

Thanking you,
Yours faithfully,

For Blue Jet Healthcare Limited

Sweta Poddar
Company Secretary & Compliance Officer
Mem. No. F12287

Unit I
3/2, Milestone, Kalyan Murbad Road, Village Varap, P.O. Box No. 5, Shahad-421 103, Tel.: 91 251 2280283 Fax : +91 251 2280567
Unit II
Plot No. B-12, C-4, E-2, MIDC, Industrial Area, Chemical Zone, Ambernath (W) 421501. Tel. : +91 8956363877/8956363878
Unit III
K-4/1, Additional MIDC Road, Mahad Industrial Area, Mahad- 402309, Tel.: + 91 22 2207 5307 / 6192 / 1691 Fax : +91 22 2207 0294

Email : info@bluejethealthcare.com / Website : www.bluejethealthcare.com

kkc & associates llp

Chartered Accountants

(formerly Khimji Kunverji & Co LLP)

Independent Auditor's Review Report on unaudited financial results for the quarter ended 31 December 2025 and year to date results for the period from 01 April 2025 to 31 December 2025 of Blue Jet Healthcare Limited under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

To
The Board of Directors of
Blue Jet Healthcare Limited

Introduction

1. We have reviewed the accompanying statement of unaudited financial results of Blue Jet Healthcare Limited ('the Company') for the quarter ended 31 December 2025 and year to date results for the period from 01 April 2025 to 31 December 2025 ('the Statement'), being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('Listing Regulations').
2. This Statement, which is the responsibility of the Company's Management and approved by the Board of Directors of the Company, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard ('Ind AS') 34 'Interim Financial Reporting' specified in section 133 of the Companies Act, 2013 ('the Act'), read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.

Scope of Review


3. We conducted our review of the Statement in accordance with the Standard on Review Engagements ('SRE') 2410 - 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity' issued by the Institute of Chartered Accountants of India ('the ICAI'). This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of company's personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Conclusion

4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Ind AS specified under Section 133 of the Act as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For **KKC & Associates LLP**

Chartered Accountants
(formerly Khimji Kunverji & Co LLP)
Firm Registration Number: 105146W/W100621



Kamlesh R Jagetia

Partner

ICAI Membership No: 139585

UDIN: 26139585ZODRXN1201

Place: Mumbai

Date: 13 February 2026



BLUE JET HEALTHCARE LIMITED
STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THREE MONTHS AND NINE MONTHS ENDED 31-12-2025

₹ in million

Particulars	Three Months Ended			Nine Months Ended		Year Ended
	31-12-2025	30-09-2025	31-12-2024	31-12-2025	31-12-2024	31-03-2025
	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1 Revenue from Operations	1,924.14	1,654.81	3,183.82	7,126.53	6,895.40	10,299.85
2 Other Income	132.09	242.71	132.41	457.34	340.31	462.56
3 Total Income (1+2)	2,056.23	1,897.52	3,316.23	7,583.87	7,235.71	10,762.41
4 Expenses						
Cost of Materials Consumed	789.32	1,084.24	1,712.44	2,952.46	3,767.64	5,402.45
Changes [Decrease /(Increase)] in Inventories of Finished goods and Work-in-Progress	139.17	(505.58)	(268.24)	383.66	(690.16)	(790.24)
Employee Benefits Expense	190.72	185.54	148.25	550.52	450.05	609.97
Finance Costs	3.39	46.27	0.16	56.56	0.64	0.98
Depreciation and Amortisation Expense	59.83	58.66	47.45	175.47	128.42	177.89
Other Expenses	336.03	341.12	351.23	1,011.56	990.24	1,300.37
Total Expenses	1,518.46	1,210.25	1,991.29	5,130.23	4,646.83	6,701.42
5 Profit before Tax (3-4)	537.77	687.27	1,324.94	2,453.64	2,588.88	4,060.99
6 Tax Expense:						
Current Tax	119.90	179.10	325.00	597.00	600.00	965.00
Short/ (Excess) Tax Provision related to prior years	-	-	-	-	-	2.75
Deferred Tax (credit)/ charge	16.21	(13.19)	10.11	21.91	37.78	41.21
Total Tax Expense	136.11	165.91	335.11	618.91	637.78	1,008.96
7 Profit for the period/ year (5-6)	401.66	521.36	989.83	1,834.73	1,951.10	3,052.03
8 Other Comprehensive Income						
(i) Items that will not be reclassified to profit or loss	(5.40)	1.48	-	(3.92)	-	0.42
(ii) Income Tax relating to items that will not be reclassified to profit or loss	1.36	(0.37)	-	0.99	-	(0.10)
Other Comprehensive Income for the period/ year	(4.04)	1.11	-	(2.93)	-	0.32
9 Total Comprehensive Income for the period/ year (7 + 8)	397.62	522.47	989.83	1,831.80	1,951.10	3,052.35
10 Paid-up Equity Share Capital (Face Value ₹ 2 per share)	346.93	346.93	346.93	346.93	346.93	346.93
11 Other Equity						10,984.18
12 Earnings per Share (EPS) of Face value ₹ 2/- each*						
(a) Basic - (₹)	2.32	3.01	5.71	10.58	11.25	17.59
(b) Diluted - (₹)	2.32	3.01	5.71	10.58	11.25	17.59

*EPS are not annualised for interim periods

Notes:

- The above financial results of the Company for the three months and nine months ended December 31, 2025 have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their respective meetings held on February 13, 2026. Further, the above financial results have been reviewed by the Statutory Auditor of the Company.
- The company is engaged in manufacturing of Artificial Sweetener, Contrast Media Intermediate, Pharma Intermediate, APIs used in Pharmaceutical and Healthcare products and the same constitutes a single reportable business segment as per IND AS 108.
- The Company does not have any subsidiaries, associates, or joint ventures as on December 31, 2025. Consequently, the preparation of consolidated financial statements is not applicable.

Navi Mumbai

Date: February 13, 2026



For and on behalf of Board of Directors

Shiven Arora
Shiven Arora

Managing Director